{"id":336185,"date":"2024-07-02T00:00:00","date_gmt":"2024-07-02T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0024-biopharma-atrial-fibrillation-epidemiology-mature-markets\/"},"modified":"2026-03-31T10:29:20","modified_gmt":"2026-03-31T10:29:20","slug":"epidcv0024-biopharma-atrial-fibrillation-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0024-biopharma-atrial-fibrillation-epidemiology-mature-markets\/","title":{"rendered":"Atrial Fibrillation &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of atrial fibrillation (<abbr title=\"atrial fibrillation\">AF<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of <abbr title=\"atrial fibrillation\">AF<\/abbr> for each country, as well as annualized case counts projected to the national population. Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in the major pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"atrial fibrillation\">AF<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will change in the levels of exposure to known risk or protective factors affect the number of people living with <abbr title=\"atrial fibrillation\">AF<\/abbr>?<\/li>\n<li>Of all people with <abbr title=\"atrial fibrillation\">AF<\/abbr>, how many in each country have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr title=\"atrial fibrillation\">AF<\/abbr>, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"atrial fibrillation\">AF<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS<\/span> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology provides at least 20 years of forecast data for the following <abbr data-abbreviation-entity=\"4724\" title=\"atrial fibrillation\">AF<\/abbr> patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases of <abbr title=\"atrial fibrillation\">AF<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"atrial fibrillation\">AF<\/abbr>.<\/li>\n<li>Undiagnosed prevalent cases of <abbr title=\"atrial fibrillation\">AF<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"atrial fibrillation\">AF<\/abbr> by subtype scheme.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"atrial fibrillation\">AF<\/abbr> by hypertension status.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"atrial fibrillation\">AF<\/abbr> by valvular heart disease status.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"atrial fibrillation\">AF<\/abbr> by heart failure status.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"atrial fibrillation\">AF<\/abbr> by <abbr title=\"New York Heart Association\">NYHA<\/abbr> subpopulation.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"atrial fibrillation\">AF<\/abbr> by <abbr title=\"Congestive heart failure, high blood pressure, age 45 or older, diabetes, previous stroke or transient ischemic attack\">CHADS2<\/abbr> score.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"atrial fibrillation\">AF<\/abbr> by <abbr title=\"Congestive heart failure, high blood pressure, age 45 or older, diabetes, previous stroke or transient ischemic attack, vascular disease, age 65-74, sex (female)\">CHA2DS2-VASc<\/abbr> score.<\/li>\n<li>Diagnosed and drug-treated prevalent cases of <abbr title=\"atrial fibrillation\">AF<\/abbr>.<\/li>\n<li>Diagnosed and non-drug-treated prevalent cases of <abbr title=\"atrial fibrillation\">AF<\/abbr>.<\/li>\n<li>Diagnosed incident cases of <abbr title=\"atrial fibrillation\">AF<\/abbr>.<\/li>\n<\/ul>\n<p>\u2026 and many more (details available on request).<\/p>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-336185","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-atrial-fibrillation","biopharma-therapy-areas-cardiovascular","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/336185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/336185\/revisions"}],"predecessor-version":[{"id":336445,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/336185\/revisions\/336445"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=336185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}